Generalized Anxiety Disorder Market Report and Forecast 2024-2032
Generalized Anxiety Disorder Market Report and Forecast 2024-2032
Generalized Anxiety Disorder Market Outlook
The generalized anxiety disorder market size was valued at USD 1717.5 million in 2023, driven by growing recognition of generalized anxiety disorder as a serious mental health condition. The market size is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032 to achieve a value of USD 2751.1 million by 2032.
Generalized Anxiety Disorder: Introduction
Generalized anxiety disorder (GAD) is a chronic mental health condition characterized by persistent and excessive worry about various aspects of daily life, often without a specific cause. Individuals with GAD find it difficult to control their anxiety, leading to symptoms such as restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbances. GAD can significantly impair daily functioning and is often accompanied by other mood or anxiety disorders, necessitating professional evaluation and treatment.
Key Trends in the Generalized Anxiety Disorder Market
Globally, there's a growing recognition of GAD as a serious mental health condition. Enhanced awareness among the public and healthcare professionals is leading to more frequent diagnosis and a higher reported prevalence.
There's a trend towards personalized treatment plans, combining pharmacotherapy (like SSRIs and SNRIs) with psychotherapy (particularly Cognitive Behavioral Therapy). Research into new medication classes and therapy forms is ongoing, aiming to improve outcomes and reduce side effects.
The adoption of digital tools, including mobile apps for anxiety management and teletherapy services, is on the rise. These tools offer accessible and flexible treatment options, particularly important in regions with limited mental health resources.
There's a growing emphasis on holistic and integrated care approaches, combining mental health services with primary care to ensure comprehensive management of GAD, especially given its frequent comorbidity with other health conditions.
Various regions are witnessing increased governmental and non-governmental investment in mental health services, aiming to improve access to care and support mental health research.
Efforts to reduce stigma around mental health and promote mental wellbeing are contributing to a more open environment for discussing and treating GAD.
Generalized Anxiety Disorder Market Segmentation
Market Breakup by Therapeutic Type
- Antidepressant
- Buspirone
- Benzodiazepines
- Interpersonal Therapy
- Behavior Therapy
- Cognitive Behavioral Therapy
- Mindfulness Based Cognitive Therapy
- Deep Brain Stimulation
- Electroconvulsive Therapy
- Transcranial Magnetic
- Stimulation Vagus Nerve
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
North America market is well-established, particularly in the U.S. and Canada, with a high awareness of mental health issues and a wide range of treatment options available, including medication, psychotherapy, and integrated care models. There's a growing focus on personalized medicine and digital health solutions like teletherapy.
Europe shows a strong emphasis on healthcare provision and mental health services, with countries like the UK, Germany, and France leading in terms of GAD treatment and research. The region is known for its comprehensive healthcare systems that include mental health services and a growing acceptance of mental health issues.
Japan market is growing, driven by increasing awareness of mental health conditions and improvements in healthcare infrastructure. The region is investing in mental health services, though cultural stigmas around mental health can impact the willingness to seek treatment.
Generalized Anxiety Disorder Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Eli Lilly and Company
- GlaxoSmithKline Pharmaceuticals Limited
- Pfizer, Inc.
- Abbott Laboratories
- Bristol-Myers Squibb
- Actavis Pharmaceutical Company
- F. Hoffmann-La Roche
- Sumitomo Dainippon Pharma
- MindMed
- VistaGen Therapeutics, Inc
- Mitsubishi Chemical Group Corporation
- Sanofi
- Mitsubishi Chemical Group Corporation
- Forest Laboratories, Inc
- H. Lundbeck A/S
*Please Note:* The report will take 7 business days to complete, after order confirmation.
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Generalized Anxiety Disorder Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Generalized Anxiety Disorder Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2017-2032)
- 5.2 United States Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
- 5.3 EU-4 and United Kingdom Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
- 5.3.1 Germany Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
- 5.3.2 France Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
- 5.3.3 Italy Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
- 5.3.4 Spain Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
- 5.3.5 United Kingdom Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
- 5.4 Japan Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
- 6 Generalized Anxiety Disorder Market Overview – 7MM
- 6.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
- 6.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
- 7 Generalized Anxiety Disorder Market Landscape – 7MM
- 7.1 Generalized Anxiety Disorder: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Generalized Anxiety Disorder Product Landscape
- 7.2.1 Analysis by Treatment Type
- 7.2.2 Analysis by Route of Administration
- 7.2.3 Analysis by Treatment Type
- 8 Generalized Anxiety Disorder Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Generalized Anxiety Disorder Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Generalized Anxiety Disorder Market Segmentation – 7MM
- 11.1 Generalized Anxiety Disorder Market by Therapeutic Type
- 11.1.1 Market Overview
- 11.1.2 Antidepressant
- 11.1.3 Buspirone
- 11.1.4 Benzodiazepines
- 11.2 Generalized Anxiety Disorder Market by Therapy Type
- 11.2.1 Market Overview
- 11.2.2 Interpersonal Therapy
- 11.2.3 Behavior Therapy
- 11.2.4 Cognitive Behavioral Therapy
- 11.2.5 Mindfulness Based Cognitive Therapy
- 11.3 Generalized Anxiety Disorder Market by Diagnosis
- 11.3.1 Market Overview
- 11.3.2 Deep Brain Stimulation
- 11.3.3 Electroconvulsive Therapy
- 11.3.4 Transcranial Magnetic
- 11.3.5 Stimulation Vagus Nerve
- 11.4 Generalized Anxiety Disorder Market by Region
- 11.4.1 Market Overview
- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 12 United States Generalized Anxiety Disorder Market
- 12.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
- 12.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
- 12.3 Generalized Anxiety Disorder Market by Disease Type
- 12.4 Generalized Anxiety Disorder Market by Treatment Type
- 13 EU-4 and United Kingdom Generalized Anxiety Disorder Market
- 13.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
- 13.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
- 13.3 Germany Generalized Anxiety Disorder Market Overview
- 13.3.1 Generalized Anxiety Disorder Market by Disease Type
- 13.3.2 Generalized Anxiety Disorder Market by Treatment Type
- 13.4 France Generalized Anxiety Disorder Market Overview
- 13.4.1 Generalized Anxiety Disorder Market by Disease Type
- 13.4.2 Generalized Anxiety Disorder Market by Treatment Type
- 13.5 Italy Generalized Anxiety Disorder Market Overview
- 13.5.1 Generalized Anxiety Disorder Market by Disease Type
- 13.5.2 Generalized Anxiety Disorder Market by Treatment Type
- 13.6 Spain Generalized Anxiety Disorder Market Overview
- 13.6.1 Generalized Anxiety Disorder Market by Disease Type
- 13.6.2 Generalized Anxiety Disorder Market by Treatment Type
- 13.7 United Kingdom Generalized Anxiety Disorder Market Overview
- 13.7.1 Generalized Anxiety Disorder Market by Disease Type
- 13.7.2 Generalized Anxiety Disorder Market by Treatment Type
- 14 Japan Generalized Anxiety Disorder Market
- 14.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
- 14.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
- 14.2.1 Generalized Anxiety Disorder Market by Disease Type
- 14.2.2 Generalized Anxiety Disorder Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Eli Lilly and Company
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 GlaxoSmithKline Pharmaceuticals Limited
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 Pfizer, Inc.
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 Abbott Laboratories
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 Bristol-Myers Squibb
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 Actavis Pharmaceutical Company
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 F. Hoffmann-La Roche
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 Sumitomo Dainippon Pharma
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 MindMed
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 VistaGen Therapeutics, Inc
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Mitsubishi Chemical Group Corporation
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 Sanofi
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Mitsubishi Chemical Group Corporation
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 Forest Laboratories, Inc
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 20.15 H. Lundbeck A/S
- 20.15.1 Financial Analysis
- 20.15.2 Product Portfolio
- 20.15.3 Demographic Reach and Achievements
- 20.15.4 Mergers and Acquisition
- 20.15.5 Certifications
- 21 Generalized Anxiety Disorder Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook